Background: Atherosclerosis as a complication of diabetes, is considered to be a chronic inflammatory disease, developing over years and proceeding through many steps. Adiposity fatty acid-binding protein (A-FABP) is highly expressed in mature adipocytes and plays a central regulatory role in energy metabolism and inflammation. A-FABP mRNA expression in adipose tissues predicted coronary artery disease in homozygous subjects. A-FABP may also play a role in the development of atherosclerotic diseases in humans. Objective: To detect the relationship between serum A-FABP level and carotid intima-media thickness (IMT) as indicator of atherosclerosis in patients with type 2 diabetes mellitus. Patients and methods: 124 patients with type 2 diabetes (T2D), were divided into two groups: Group 1: 62 patients with T2D ≤ 5 years duration, and Group 2: 62 patients with T2D > 5 years duration. They were subjected to full history taking, clinical examination, and laboratory investigations in the form of CBC, LFT, KFT, HBA1c, fasting and postprandial blood sugar, A-FABP serum level, and carotid Doppler. Results: Serum level A-FABP and carotid IMT was significantly higher in long standing diabetes group compared to short standing diabetes group. A-FABP cutoff was proven to have a high sensitivity 94.4%, specificity 100.0%, positive predictive value of 100.0%, negative predictive value of 97.7% and overall accuracy of 98.3% regarding the prediction of atherosclerosis. Conclusions: A-FABP serum level have a high sensitivity, specificity, predictive value and overall accuracy regarding atherosclerosis, and should be recommended as a part of routine surveillance for atherosclerosis in patients with type 2 diabetes.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.